

References

I-261

1. Tzielid (teplizumab-mzwv) injection, for intravenous use [package insert]. Prevention Bio Inc. Red Bank, NJ. Revised 11/2022.
2. Clinical Pharmacology™ Compendium. 2022. Tampa FL: Gold Standard, Inc. Teplizumab.
3. Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for Type 1 Diabetes. *N Engl J Med.* 2019; 381(7):603-613.
4. Micromedex DrugDex Compendium®. 2022. Teplizumab-mzwv.
5. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. *Diabetes Care.* 2022;45(suppl1):S17–S38y.
6. Teplizumab-mzwv In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 24, 2022.